Detection of cytomegalovirus drug resistance mutations by next-Generation sequencing

Journal of Clinical Microbiology

Volumn 51, Issue 11, 2013, Pages 3700-3710

  Sahoo, Malaya K ^a   Lefterova, Martina I ^a   Yamamoto, Fumiko ^a   Waggoner, Jesse J ^a   Chou, Sunwen ^b   Holmes, Susan P ^c   Anderson, Matthew W ^a,d   Pinsky, Benjamin A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c STANFORD UNIVERSITY   (United States)

^d BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ADULT; ALGORITHM; AMPLICON; ANALYTICAL ERROR; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; GENE LIBRARY; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; MICROFLUIDICS; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UL54 GENE; UL97 GENE; VIRUS GENE; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SENSITIVITY AND SPECIFICITY; VIRAL PROTEINS; YOUNG ADULT;

EID: 84886474257     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01605-13     Document Type: Article

References (60)

1. Boeckh M, Geballe AP.2011.Cytomegalovirus: pathogen, paradigm, and puzzle.J.Clin.Invest.121:1673-1680.
2. Baroco AL, Oldfield EC.2008.Gastrointestinal cytomegalovirus diseasein the immunocompromised patient.Curr.Gastroenterol.Rep.10:409-416.
3. Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G.2004.Cytomegalovirus infection after bone marrow transplantation in children.Hum.Immunol.65:416-422.
4. Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM.2013.Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients.Cochrane Database Syst.Rev.2:CD005133.doi:10. 1002/14651858.CD006133.pub3.
5. Hodson EM, Ladhani M, Webster AC, Strippoli GF, Craig JC.2013.Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.Cochrane Database Syst.Rev.2:CD003774.doi: 10.1002/14651858.CD003774. pub3.
6. Lurain NS, Chou S.2010.Antiviral drug resistance of human cytomegalovirus.Clin.Microbiol.Rev.23:689-712.
7. Drew WL.2010.Cytomegalovirus resistance testing: pitfalls and problems for the clinician.Clin. Infect. Dis.50:733-736.
8. Kotton CN.2010.Management of cytomegalovirus infection in solid organ transplantation.Nat.Rev.Nephrol.6:711-721.
9. Yu MA, Park JM.2013.Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.Expert Opin.Pharmacother 14:807-815.
10. Biron KK, Stanat SC, Sorrell JB, Fyfe JA, Keller PM, Lambe CU, Nelson DJ.1985.Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1- (hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus.Proc. Natl. Acad. Sci. U.S.A.82: 2473-2477.
11. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A, Transplantation Society International CMV Consensus Group.2010.International consensus guidelines on the management of cytomegalovirus in solid organ transplantation.Transplantation 89:779-795.
12. Crumpacker CS.1996.Ganciclovir.N.Engl.J.Med.335:721-729.
13. Field AK, Davies ME, DeWitt C, Perry HC, Liou R, Germershausen J, Karkas JD, Ashton WT, Johnston DB, Tolman RL.1983.9-([2-hydroxy-1-(hydroxymethyl) ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication.Proc. Natl. Acad. Sci. U.S.A.80:4139-4143.
14. Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.2011.Incidence and outcomes of ganciclovirresistant cytomegalovirus infections in 1244 kidney transplant recipients.Transplantation 92:217-223.
15. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M.2000.Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.Lancet 356:645-649.
16. Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP.2007.Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.Clin. Infect. Dis.45:439-447.
17. Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germi R, Pillet S, Lebranchu Y, Turlure P, Alain S, French CMV Resistance Survey Study Group.2010.Drug-resistant cytomegalovirus in transplant recipients: a French cohort study.J. Antimicrob. Chemother.65:2628-2640.
18. Boivin G, Gilbert C, Gaudreau A, Greenfield I, Sudlow R, Roberts NA.2001.Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis.J. Infect. Dis.184:1598-1602.
19. Gilbert C, Handfield J, Toma E, Lalonde R, Bergeron MG, Boivin G.1998.Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients.AIDS 12:125-129.
20. Jabs DA, Dunn JP, Enger C, Forman M, Bressler N, Charache P.1996.Cytomegalovirus retinitis and viral resistance.Prevalence of resistance at diagnosis, 1994.Cytomegalovirus Retinitis and Viral Resistance Study Group.Arch.Ophthalmol.114:809-814.
21. Martin BK, Ricks MO, Forman MS, Jabs DA, Cytomegalovirus Retinitis and Viral Resistance Study Group.2007.Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis.Clin. Infect. Dis.44:1001-1008.
22. Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P, Ward K, European Group for Blood and Marrow Transplantation.2004.Management of CMV infections: recommendations from the infectious diseases working party of the EBMT.Bone Marrow Transplant.33:1075-1081.
23. Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ, Terry Beirn Community Programs for Clinical Research on AIDS.2009.Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.J. Infect. Dis.199:693-701.
24. Vrancken B, Lequime S, Theys K, Lemey P.2010.Covering all bases in HIV research: unveiling a hidden world of viral evolution.AIDS Rev.12:89-102.
25. Görzer I, Guelly C, Trajanoski S, Puchhammer-Stöckl E.2010.Deep sequencing reveals highly complex dynamics of human cytomegalovirus genotypes in transplant patients over time.J. Virol.84:7195-7203.
26. Renzette N, Bhattacharjee B, Jensen JD, Gibson L, Kowalik TF.2011.Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants.PLoS Pathog.7:e1001344.doi:10.1371/journal.ppat .1001344.
27. Strasfeld L, Lee I, Tatarowicz W, Villano S, Chou S.2010.Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir.J. Infect. Dis.202:104-108.
28. Erice A, Gil-Roda C, Pérez JL, Balfour HH, Jr, Sannerud KJ, Hanson MN, Boivin G, Chou S.1997.Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.J. Infect. Dis.175:1087-1092.
29. Chou S, Marousek G, Guentzel S, Follansbee SE, Poscher ME, Lalezari JP, Miner RC, Drew WL.1997.Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.J. Infect. Dis.176:786-789.
30. Chou S.2010.Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.Antimicrob. Agents Chemother.54:2371-2378.
31. Waggoner J, Ho DY, Libiran P, Pinsky BA.2012.Clinical significance of low cytomegalovirus DNA levels in human plasma.J. Clin. Microbiol.50:2378-2383.
32. Hakki M, Chou S.2011.The biology of cytomegalovirus drug resistance.Curr.Opin.Infect.Dis.24:605-611.
33. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW.2007. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance.Genome Res.17:1195-1201.
34. McCullagh P, Nelder JA.1989.Generalized linear model, vol 2.Chapman & Hall/CRC, Boca Raton, FL.
35. Ihaka R, Gentleman R.1996.R: a language for data analysis and graphics.J.Comput.Graph.Stat.5:299-314.
36. Venables WN, Ripley BD.2002.Modern Applied Statistics with S, 4th ed.Springer, New York, NY.
37. Gilbert C, Azzi A, Goyette N, Lin SX, Boivin G.2011.Recombinant phenotyping of cytomegalovirus UL54 mutations that emerged during cell passages in the presence of either ganciclovir or foscarnet.Antimicrob. Agents Chemother.55:4019-4027.
38. Chevillotte M, Ersing I, Mertens T, von Einem J.2010.Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase.Antimicrob. Agents Chemother.54: 5004-5011.
39. Boutolleau D, Burrel S, Agut H.2011.Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir.Antiviral Res.91:32-35.
40. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DR.2009.Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.PLoS One 4:e5683.doi:10 .1371/journal.pone.0005683
41. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R.2011.Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.Proc. Natl. Acad. Sci. U.S.A.108:20166-20171.
42. Mousavi-Jazi M, Schloss L, Drew WL, Linde A, Miner RC, Harmenberg J, Wahren B, Brytting M.2001.Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity.J. Clin. Virol.23:1-15.
43. Springer KL, Chou S, Li S, Giller RH, Quinones R, Shira JE, Weinberg A.2005.How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients.J. Clin. Microbiol.43:208-213.
44. Cihlar T, Fuller MD, Cherrington JM.1998.Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.J. Virol.72:5927-5936.
45. Chou S, Marousek G, Li S, Weinberg A.2008.Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.J. Clin. Virol.43:107-109.
46. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL.2003.Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus.J. Infect. Dis.188:32-39.
47. Mitsuya Y, Varghese V, Wang C, Liu TF, Holmes SP, Jayakumar P, Gharizadeh B, Ronaghi M, Klein D, Fessel WJ, Shafer RW.2008.Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations.J. Virol.82:10747-10755.
48. Fisher R, van Zyl GU, Travers SA, Kosakovsky Pond SL, Engelbrech S, Murrell B, Scheffler K, Smith D.2012.Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen.J. Virol.86:6231-6237.
49. Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, Dieckhaus K, Rosen MI, Kozal MJ.2009.Low-abundance HIV drugresistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.PLoS One 4:e6079.doi:10.1371/journal.pone .0006079.
50. Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, Egholm M, Hanczaruk B, Blake LA, Gharizadeh B, Babrzadeh F, Bachmann MH, Fessel WJ, Shafer RW.2009.Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.J.Acquir.Immune Defic.Syndr.52:309-315.
51. Lataillade M, Chiarella J, Yang R, Schnittman S, Wirtz V, Uy J, Seekins D, Krystal M, Mancini M, McGrath D, Simen B, Egholm M, Kozal M.2010.Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.PLoS One 5:e10952.doi:10.1371/journal.pone.0010952.
52. Hedskog C, Mild M, Jernberg J, Sherwood E, Bratt G, Leitner T, Lundeberg J, Andersson B, Albert J.2010.Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.PLoS One 5:e11345.doi:10.1371/journal.pone.0011345.
53. Hoffmann C, Minkah N, Leipzig J, Wang G, Arens MQ, Tebas P, Bushman FD.2007.DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations.Nucleic Acids Res.35:e91.doi:10.1093/nar/gkm435.
54. Hamady M, Walker JJ, Harris JK, Gold NJ, Knight R.2008.Errorcorrecting barcoded primers for pyrosequencing hundreds of samples in multiplex.Nat. Methods 5:235-237.
55. Dudley DM, Chin EN, Bimber BN, Sanabani SS, Tarosso LF, Costa PR, Sauer MM, Kallas EG, O'Connor DH.2012.Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance.PLoS One 7:e36494.doi:10.1371/journal.pone.0036494.
56. Mild M, Hedskog C, Jernberg J, Albert J.2011.Performance of ultradeep pyrosequencing in analysis of HIV-1 pol gene variation.PLoS One 6:e22741.doi:10.1371/journal.pone.0022741.
57. Vandenbroucke I, Van Marck H, Mostmans W, Van Eygen V, Rondelez E, Thys K, Van Baelen K, Fransen K, Vaira D, Kabeya K, De Wit S, Florence E, Moutschen M, Vandekerckhove L, Verhofstede C, Stuyver LJ.2010.HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays.AIDS Res.Ther.7:4.doi:10 .1186/1742-6405-7-4
58. Tang MW, Liu TF, Shafer RW.2012.The HIVdb system for HIV-1 genotypic resistance interpretation.Intervirology 55:98-101.
59. Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, Hall TA, Trevino C, Shafer RW, Harrigan PR.2012.Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.J. Clin. Microbiol.50:1936-1942.
60. Zazzi M, Kaiser R, Sönnerborg A, Struck D, Altmann A, Prosperi M, Rosen-Zvi M, Petroczi A, Peres Y, Schülter E, Boucher CA, Brun-Vezinet F, Harrigan PR, Morris L, Obermeier M, Perno CF, Phanuphak P, Pillay D, Shafer RW, Vandamme AM, van Laethem K, Wensing AM, Lengauer T, Incardona F.2011.Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study).HIV Med.12:211-218.